You searched for "nAMD"

501 results found

The Irlen Experience

My father used to say that humanity is divided into those that see the world through a moral framework and recognise their place within it, and Tories. When a concerned mother came to the paediatric clinic bearing literature from the...

How a calcified Soemmerring ring was removed from the vitreous cavity when the cutter and forceps failed to do so

Know’st thou the land where lemon-trees do bloom,And oranges like gold in leafy gloom; A gentle wind from deep blue heaven blows, The myrtle thick, and high the laurel grows? ‘Tis there! ‘tis there, O my beloved one, I with...

Ophthalmology (third edition)

If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...

Data update for leading causes of CVI in England and Wales

In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...

Systemic pharmacology of intravitreal anti-VEGF

This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

Exploring the potential of neurodegenerative disease screening within age-related eye disease research

The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...

The blue-light hazard – is it true?

Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: The blue-light hazard – is it true? Blue light is part of the visible optical spectrum...

What's trending Jun/Jul 2023

A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #whoopigoldberg #presbyopia #bionic Whoopi Goldberg made a name for herself in blockbusters such as the Oscar-winning Ghost and Sister Act. She...

Technology in ophthalmology – a promising future and what we need to know about the regulations

Undoubtedly, ophthalmology is one of the greatest sources of inspiration for technological progress in medicine. Thus far, we have seen remarkable advancements in the technology used by ophthalmologists across all subspecialties. From simplifying common procedures, to treating previously incurable conditions,...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...